Aisling Capital Management as of Sept. 30, 2022
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 17 positions in its portfolio as reported in the September 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 40.1 | $60M | 6.1M | 9.94 | |
| Syndax Pharmaceuticals (SNDX) | 16.4 | $25M | 1.0M | 24.03 | |
| Verona Pharma Sponsored Ads (VRNA) | 9.0 | $14M | 1.3M | 10.22 | |
| Monte Rosa Therapeutics (GLUE) | 8.0 | $12M | 1.5M | 8.17 | |
| Aclaris Therapeutics (ACRS) | 6.6 | $10M | 635k | 15.74 | |
| Biomea Fusion (BMEA) | 5.2 | $7.8M | 799k | 9.78 | |
| Nuvation Bio Com Cl A (NUVB) | 3.8 | $5.7M | 2.5M | 2.24 | |
| Poseida Therapeutics I (PSTX) | 2.4 | $3.7M | 1.0M | 3.53 | |
| Elevation Oncology (ELEV) | 2.1 | $3.2M | 2.8M | 1.13 | |
| Reneo Pharmaceuticals (RPHM) | 2.0 | $3.0M | 886k | 3.35 | |
| Spruce Biosciences (SPRB) | 1.1 | $1.7M | 1.2M | 1.37 | |
| Viracta Therapeutics (VIRX) | 0.8 | $1.2M | 289k | 4.27 | |
| Marker Therapeutics Ord | 0.8 | $1.2M | 3.1M | 0.37 | |
| Aeglea Biotherapeutics | 0.6 | $890k | 1.7M | 0.53 | |
| Avrobio Ord (AVRO) | 0.4 | $646k | 1.0M | 0.64 | |
| Atreca Cl A Com (BCEL) | 0.4 | $609k | 388k | 1.57 | |
| Talaris Therapeutics | 0.3 | $460k | 175k | 2.63 |
